Safety
death, Belom cell number, pneumonia, anemia
HYPOALBUMINEMIA, PNEUMONIA, ADVERSE EVENTS, DRUG WITHDRAWAL, HYPOPARATHYROIDISM, ANEMIA, UPPER GASTROINTESTINAL BLEEDING
A total of 29 patients (96.7%) experienced any grade treatment-related adverse events (TRAEs), most of which were grade 1–2. The incidence of grade 3 or higher adverse events was 23.3%. It mainly includes three lymphocyte count decreased, 1 hypoalbuminemia, 1 anemia, 1 Belom cell number decreased, 1 aspartate aminotransferase increased, 2 neutrophil count decreased, 1 platelet count decreased, and 1 thyroid-stimulating hormone increased. There were four cases of adverse events leading to drug withdrawal, including hypoparathyroidism, pneumonia, and upper gastrointestinal bleeding. Immune-related adverse events occurred in 60% of patients and were mostly grade 1–2. Only one case of grade 3 or above irAE occurred, which was the thyroid-stimulating hormone decreased. There was no AE incidence resulting in death (≥10% treatment-related adverse events and potential immune-related adverse events.